All compounds were able to significantly inhibit immune-complex induced NET production in HC, RA and SLE neutrophils (Fig. 2B, P < 0.05, n = 5 each group) with the exception of the pan-EGFR inhibitor AZD-8931, which had no statistical effect in SLE neutrophils (P = 0.052). This evidence concerns the gene EGFR and rheumatoid arthritis.